logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9676802 B1

PDFFull Text
Expired
Date of Patent:
Jun. 13, 2017

Filed:

Apr. 16, 2014

Hepatitis c virus inhibitors

Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Yao-Ling Qiu, Andover, MA (US);

Hui Cao, Belmont, MA (US);

Xiaowen Peng, Cambridge, MA (US);

Zhigang Chen, Acton, MA (US);

Yat Sun Or, Watertown, MA (US);

Assignee:

ENANTA PHARMACEUTICALS, INC., Watertown, MA (US);

Attorneys:

Edgar W. Harlan

Carolyn S. Elmore

Elmore Patent Law Group, P.C.

Primary Examiner:

Hasan Ahmed

Assistant Examiner:

Kaipeen Yang

Int. Cl.
CPC ...
A01N 43/56 (2006.01); A61K 31/415 (2006.01); C07F 9/6561 (2006.01); A61K 31/426 (2006.01); C07D 498/08 (2006.01); C07D 498/18 (2006.01); C07D 519/00 (2006.01); A61K 38/21 (2006.01); A61K 31/13 (2006.01); A61K 31/7056 (2006.01); A61K 38/55 (2006.01); A61K 31/4188 (2006.01); A61K 31/4196 (2006.01); A61K 31/422 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07F 9/65616 (2013.01); A61K 31/13 (2013.01); A61K 31/4188 (2013.01); A61K 31/4196 (2013.01); A61K 31/422 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/428 (2013.01); A61K 31/4245 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 31/7056 (2013.01); A61K 38/21 (2013.01); A61K 38/55 (2013.01); A61K 45/06 (2013.01); C07D 498/08 (2013.01); C07D 498/18 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:Q-G-A-L-B—Z—W  (I),which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Find Patent Forward Citations

Qiu, Yao-Ling. (2017). Hepatitis c virus inhibitors (U.S. Patent No. 9676802). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9676802

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…